You are here: Industry Insights > Pharma in China

News List

TAF: The Strongest HBV Drug in History PharmaSources/Xiaobing
July 24, 2019
With Lower Risks of Liver Cirrhosis and Hepatocellular Carcinoma
A Review of MS drugs in China PharmaSources/Caicai
July 24, 2019
There are only two MS drugs approved for marketing in China, separately being the interferon beta-1a and teriflunomide...
A Blockbuster to Arrive in the Multiple Sclerosis Area of China! PharmaSources/Caicai
July 24, 2019
Novartis’ Fingolimod with Annual Sales Exceeding USD3 Billion to be Marketed Soon in China
Market Shares of Overseas Pharma Enterprises Approach 70% in China’s Coagulation Factor Ⅷ Market PharmaSources/Caicai
July 23, 2019
The theoretical market size of coagulation factor Ⅷ exceeds RMB10 billion in China
Novo Nordisk’s Recombinant Coagulation Factor Ⅷ Applied for Marketing Ahead of Chiatai Tianqing! PharmaSources/Caicai
July 23, 2019
The Blue Ocean Market of Hemophilia Drugs Exceeding RMB10 Billion
Development Status of Pilose Antler, a Traditional Chinese Medicinal Material PharmaSources/Xiaonisha
July 18, 2019
Pilose antler is sawed in summer and autumn and dried after processing.
How was the Small Molecule Apixaban with Annual Sales of Nearly USD10 Billion “Tempered”? PharmaSources/Yuntian
July 18, 2019
As an oral, direct coagulation factor Xa inhibitor developed by BMS and Pfizer, Eliquis (apixaban) was first approved fo
A Review of U.S. ANDA Approvals Received by Chinese Pharmaceutical Enterprises in the First Half of 2019 PharmaSources/Caicai
July 16, 2019
41 Approval Numbers, Multiple Blockbuster Varieties
Overview of the Approval Trends of Pharmaceutical Products in the First Half of 2019 PharmaSources/Suyi
July 11, 2019
Clinically Imperative Overseas New Drugs Approved Accounting for a Larger Number
Mainstream psoriasis drugs marketed in the world PharmaSources/Caicai
July 10, 2019
Marketing of benvitimod, a Chinese-produced Class 1 innovative drug